Basic Information
| Drug ID | DDPD00734 |
|
| Drug Name | Risperidone | |
| Molecular Weight | 410.4845 | |
| Molecular Formula | C23H27FN4O2 | |
| CAS Number | 106266-06-2 | |
| SMILES | CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1 | |
| External Links | ||
| DRUGBANK | DB00734 | |
| T3DB | T3D2871 | |
| PubChem Compound | 5073 | |
| PDR | 276 | |
| Drugs.com | Drugs.com Drug Page | |
Experimental Physicochemical Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Reference |
|---|---|---|---|---|---|
| Boiling Point | 442.0 | ℃ | 442 | ℃ | DRUGBANK |
| Melting Point | 170.0 | ℃ | 170 | ℃ | PhysProp |
| Water Solubility | 2330.0 | mg/L | 2.33 | mg/ml | DRUGBANK |
Pharmacokinetic/ Toxicokinetic Property
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Factor | Reference |
|---|---|---|---|---|---|---|---|
| Bioavailability | 70.0 | % | 70 | % | PO, oral; | DRUGBANK | Bioavailability | 66.0 | % | 66±28 | % | PO, oral; | The Pharmacological Basis of Therapeutics | Bioavailability | 103.0 | % | 103±13 | % | IM,intramuscular injection; | The Pharmacological Basis of Therapeutics |
| C Max | 10.0 | ng/ml | 10.0 | ng/ml | PO, oral; schizophrenia; | The Pharmacological Basis of Therapeutics | C Max | 45.0 | ng/ml | 45.0 | ng/ml | PO, oral; Active metabolite; schizophrenia; | The Pharmacological Basis of Therapeutics |
| T Max | 1.0 | h | ~1 | h | PO, oral; schizophrenia; | The Pharmacological Basis of Therapeutics | |
| Clearance | 2.2 | L/h | 15-59 | ml/min | Renal clearance; Elderly; Renal metabolism; | Age ↓ ; | DRUGBANK | Clearance | 0.32 | L/h/kg | 5.4±1.4 | ml/min/kg | hydrolysis; | Elderly ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; | The Pharmacological Basis of Therapeutics | Clearance | 0.32 | L/h/kg | 5.4 | ml/min/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Volume of Distribution | 1.5 | L/kg | ~1.0-2.0 | L/kg | DRUGBANK | Volume of Distribution | 1.1 | L/kg | 1.1±0.2 | L/kg | The Pharmacological Basis of Therapeutics | Volume of Distribution | 1.1 | L/kg | 1.1 | L/kg | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Half-life | 3.0 | h | 3 | h | extensive metabolizers, EM; | DRUGBANK | Half-life | 20.0 | h | 20 | h | poor metabolizers, PM; | DRUGBANK | Half-life | 3.2 | h | 3.2±0.8 | h | RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ; | The Pharmacological Basis of Therapeutics | Half-life | 20.0 | h | 20±3 | h | Active metabolite; | RD, renal impairment, Renal disease，including uremia ↑ ;Age ↑ ; | The Pharmacological Basis of Therapeutics | Half-life | 3.2 | h | 3.2 | h | intravenous injection, IV; human, homo sapiens; | Human Intravenous Pharmacokinetic Dataset |
| Toxicity LD50 | 57.7 | mg/kg | 57.7 | mg/kg | PO, oral; Rattus, Rat; | DRUGBANK | Toxicity LD50 | 34.0 | mg/kg | 34.0 | mg/kg | intravenous injection, IV; Rattus, Rat; | DRUGBANK | Toxicity LD50 | 82.1 | mg/kg | 82.1 | mg/kg | PO, oral; mouse; | T3DB |
| Eliminate Route | 3.0 | % | 3±2 | % | Urinary excretion; Unchanged drug; | The Pharmacological Basis of Therapeutics | |
| Protein Binding | 88.0 | % | 88 | % | plasma proteins; human, homo sapiens; | DRUGBANK | Protein Binding | 89.0 | % | 89 | % | Hepatic cirrhosis, cirr ↓ ; | The Pharmacological Basis of Therapeutics |
Maximum Dosage
| Property Name | Property Value | Unit | Raw Value | Raw Unit | Annotation | Brand Name | Component | Reference |
|---|---|---|---|---|---|---|---|---|
| Max dose for children | 6.0 | mg/day | 6 | mg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for children | 3.0 | mg/day | 3 | mg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for children | 0.06 | mg/kg/day | 0.06 | mg/kg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for children | 3.0 | mg/day | 3 | mg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for children | 0.06 | mg/kg/day | 0.06 | mg/kg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for adolescents | 6.0 | mg/day | 6 | mg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for adolescents | 3.0 | mg/day | 3 | mg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for adolescents | 0.06 | mg/kg/day | 0.06 | mg/kg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for adults | 16.0 | mg/day | 16 | mg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for adults | 6.0 | mg/day | 6 | mg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for adults | 3.57142857142857 | mg/day | 50 | mg/dose | IM,intramuscular injection | Risperdal Consta | risperidone | PDR |
| Max dose for adults | 4.0 | mg/day | 120 | mg/dose | subcutaneous injection, SC; once monthly | Risperdal Consta | risperidone | PDR |
| Max dose for geriatric | 16.0 | mg/day | 16 | mg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for geriatric | 6.0 | mg/day | 6 | mg/day | PO, oral | Risperdal Consta | risperidone | PDR |
| Max dose for geriatric | 3.57142857142857 | mg/day | 50 | mg/dose | IM,intramuscular injection | Risperdal Consta | risperidone | PDR |
| Max dose for geriatric | 40.0 | mg/day | 120 | mg/dose | subcutaneous injection, SC; nan | Risperdal Consta | risperidone | PDR |
Drug Property Radar Chart
Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1